These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
976 related articles for article (PubMed ID: 31521679)
1. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679 [TBL] [Abstract][Full Text] [Related]
2. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
3. Health-Related Quality of Life Outcomes in PARADIGM-HF. Lewis EF; Claggett BL; McMurray JJV; Packer M; Lefkowitz MP; Rouleau JL; Liu J; Shi VC; Zile MR; Desai AS; Solomon SD; Swedberg K Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28784687 [TBL] [Abstract][Full Text] [Related]
4. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD; JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043 [TBL] [Abstract][Full Text] [Related]
6. Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. Thomas M; Khariton Y; Fonarow GC; Arnold SV; Hill L; Nassif ME; Chan PS; Butler J; Thomas L; DeVore AD; Hernandez AF; Albert NM; Patterson JH; Williams FB; Spertus JA ESC Heart Fail; 2021 Aug; 8(4):2670-2678. PubMed ID: 33932120 [TBL] [Abstract][Full Text] [Related]
7. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. Chandra A; Lewis EF; Claggett BL; Desai AS; Packer M; Zile MR; Swedberg K; Rouleau JL; Shi VC; Lefkowitz MP; Katova T; McMurray JJV; Solomon SD JAMA Cardiol; 2018 Jun; 3(6):498-505. PubMed ID: 29617523 [TBL] [Abstract][Full Text] [Related]
8. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. Chin KL; Zomer E; Wang BH; Liew D Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan. Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. King JB; Shah RU; Bress AP; Nelson RE; Bellows BK JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128 [TBL] [Abstract][Full Text] [Related]
12. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587 [TBL] [Abstract][Full Text] [Related]
13. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829 [TBL] [Abstract][Full Text] [Related]
14. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Neprilysin Inhibition as a Paradigm for All? Vaduganathan M; Desai AS Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488 [TBL] [Abstract][Full Text] [Related]
16. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976 [TBL] [Abstract][Full Text] [Related]
19. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Jhund PS; McMurray JJ Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980 [TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction. Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]